Clinical Study

Morinaga BB536® - Japan’s Top-Selling Clinically Proven Probiotic

Published

Format: PDF file | Document type: Clinical Study

Morinaga BB536® - Japan’s Top-Selling Clinically Proven Probiotic

Morinaga BB536® - Japan’s Top-Selling Clinically Proven Probiotic

In breastfed infants, an astonishing 90% of the bacterial colonies in the GI tract are made up of bifidobacteria.  As we age, the presence of Bifidobacterium longum​ in particular drops precipitously leaving only an average of 5% of the original colonies in an adult intestinal tract.  Since it is often replaced with harmful bacteria such as E.coli​, the case for nutritional supplementation with bifidobacterium longum​ is strong.

But not all strains within this species are created equal.  Morinaga BB536 is supported by 40 human clinical studies​ showing a range of benefits for digestive support, immunity, healthy response to seasonal challenges and infant health.  BB536 also offers unparalleled stability, showing 80% active cell counts after 48 months ​at room temperature​.

Related resources from Maypro Industries

Show more

Supplier info centre